Back

Robert J Motzer

Robert J Motzer is a medical oncologist at the Memorial Sloan Kettering Cancer Center.[12]

Robert J. Motzer, MD Robert J. Motzer, MD, is a pioneer in the world of kidney cancer.[3]After Motzer graduated from Hope in 1977, he went to medical school at the University of Michigan; he first took note of patients with cancer during clinical rotations in the Oncology/Hematology Service.[3]He earned the Career Development Award from the National Institutes of Health, the Willet F. Whitmore Award for Clinical Excellence from MSK, and the Eugene P. Schonfeld Award from the Kidney Cancer Association.[3]After the results were published, first in the Journal of Clinical Oncology in 2006 and later in The Journal of the American Medical Association and the New England Journal of Medicine, he worked to help design trials for new targeted therapies.[3]He also reported that in subgroups defined by metastases criteria, nivolumab bested everolimus regardless of the number or site of metastases.[4]

Events - Primer's event detection algorithm clusters and summarizes multiple documents describing real-world events.

Mentions - Mentions are snippets of text that map to a person.

Docs - The number of documents that match to a person in Primer's corpus of news articles.

Full tech explainer here.

Create an article for Robert J Motzer on Wikipedia

Remember to check the sources and follow Wikipedia's guidelines.

Memorial Sloan Kettering Cancer Center

Employer

  • 4

    Events

  • 499

    Mentions

  • 156

    Docs

Recent events

NEW Nivolumab continues positive OS, ORR track record in advanced RCC 05 Mar, Roshini Claire Anthony

“Nivolumab continues to show significant OS benefit, higher [objective response rate ], and improved [progression-free survival ] over everolimus with long-term follow-up,” said study author Dr Robert Motzer from the Memorial Sloan Kettering Cancer Center in New York, US. Initial results after a median follow-up of 14 months demonstrated the superiority of nivolumab over everolimus in terms of OS and ORR.[13]

03/04/2020

Event Date

Bavencio Plus Inlyta Approved as First-Line Tx for Advanced Renal Cell Carcinoma

The approval was based on data from the phase 3 JAVELIN Renal 101 study which evaluated the combination therapy in 886 patients with advanced RCC regardless of tumor PD-L1 expression . Patients were randomized to receive either avelumab plus axitinib or sunitinib monotherapy. "With today's FDA approval of avelumab in combination with axitinib, we can now offer patients with advanced RCC a first-line treatment option that combines a PD-L1 immunotherapy with a well-known VEGFR TKI to provide a significant reduction in the risk of disease progression or death and doubling of the response rate compared with sunitinib," said Robert J. Motzer, MD, Jack and Dorothy Byrne Chair in Clinical Oncology, Memorial Sloan Kettering Cancer Center, New York, US, and principal investigator for JAVELIN Renal 101. In addition to RCC, Bavencio is also approved to treat metastatic Merkel cell carcinoma and locally advanced or metastatic urothelial carcinoma.[1112]

05/15/2019

Event Date

First-Line Atezolizumab/Bevacizumab Well-Tolerated in Metastatic RCC

Among patients with PD-L1–positive disease, ORR was 43% for patients receiving atezolizumab plus bevacizumab and 35% for those in the sunitinib group. Atezolizumab plus bevacizumab demonstrated better investigator-assessed progression-free survival than sunitinib among patients with PD-L1–positive kidney cancer . "The side effects of atezolizumab plus bevacizumab were decidedly less harsh than sunitinib," Dr. Motzer said, noting fewer high-grade treatment-related adverse events and lower steroid use among patients in the atezolizumab plus bevacizumab study group, compared to patients receiving sunitinib. The findings support consideration of atezolizumab plus bevacizumab as a first-line treatment option for patients with PD-L1–positive advanced RCC, Dr. Motzer concluded.[8910]

02/06/2018

Event Date

References